Baclofen is a gamma-aminobutyric acid agonist used primarily as a muscle relaxant to treat spasticity in children and adults. Withdrawal of oral baclofen is known to cause a withdrawal syndrome in adults. Only one previous case describes a withdrawal syndrome in a term infant, manifested by seizures, associated with the use of oral baclofen in the mother. This case describes a withdrawal syndrome and the unique use of baclofen for withdrawal in a preterm infant.
INTRODUCTION
Baclofen is a gamma-aminobutyric acid (GABA) agonist used primarily as a muscle relaxant to treat spasticity in children and adults. The mechanism of action appears to be related to the activation of the GABA B receptor site, where pre-and postsynaptic receptors are linked to calcium and potassium channels. Specifically, baclofen binds to pre-synaptic receptors, inhibiting the function of calcium channels with a decrease in neurotransmitters, and post-synaptic afferent sites, inhibiting potassium channels, thereby modifying membrane polarization and transmission of action potentials. 1 Abrupt cessation of oral baclofen may result in a withdrawal syndrome, characterized by delirium, hallucinations, movement disorders and seizures. [2] [3] [4] [5] In the neonate, intrauterine exposure may provoke a withdrawal syndrome. The current literature describes a single case requiring baclofen in a neonate to control seizures unresponsive to conventional therapy, following maternal use of oral baclofen. 6 An additional case describes the use of baclofen in a term neonate to prevent withdrawal-associated seizures. 7 This report describes the unique use of baclofen in a preterm infant to treat symptoms akin to neonatal abstinence syndrome (NAS), attributed to maternal baclofen use. CASE A 1.8-kg male infant was born at 33 2/7 weeks gestation, to a 33-year-old gravida 4 para 1 female. The maternal history was significant for a traumatic cervical spine fracture, resulting in paraplegia. The mother was referred to maternal-fetal medicine to evaluate the fetus for possible dwarfism. An amniocentesis was performed, revealing a normal 46 XY male karyotype. The mother was maintained on baclofen, 30 mg orally three times daily, for muscle spasms.
The mother presented with premature rupture of membranes. She was given intramuscular betamethasone and managed expectantly. Her labor progressed and she subsequently underwent repeat cesarean section. The infant required no resuscitation in the delivery room and was admitted to the intermediate care nursery due to prematurity. The admission exam was consistent with the estimated gestational age and, notable, only for bruising.
Because of the maternal history of baclofen use, NAS scoring (using the Modified Finnegan Scoring Tool) was begun on the first day of life. Urine and meconium toxicology screens were obtained from the infant and were negative for drugs of abuse. By the third day of life, the infant had NAS scores that ranged from 5 to 11, manifested as a high-pitched cry, tremor, hypertonicity, excessive sucking, disordered sleep, hyperthermia and mottling. Baclofen, concentrated at 5 mg ml À 1 , was begun at a dose of 0.5 mg kg
per day, divided into four doses. The infant demonstrated improvement in the symptoms of withdrawal, and a weaning schedule was devised based upon pharmacokinetics and compounding constraints associated with oral baclofen. NAS scoring was continued every 4 h during the weaning period. On the fourth day of treatment, dosage was halved to 0.25 mg kg À 1 per day. Because of compounding constraints, a dosage of less than 0.12 mg (0.067 mg kg À 1 ) could not be delivered, necessitating a reduction in the number of daily doses. On the seventh day of treatment, the dosage was halved again to 0.125 mg kg À 1 per day, divided into two doses that were administered every 12 h. The infant demonstrated transient elevations in NAS scores on the ninth day of therapy, manifested by high pitched cry, hypertonicity, excessive sucking, disordered sleep, hyperthermia and loose stools. Weaning of baclofen was delayed until the 11th day, when the daily dosage was halved to 0.067 mg kg À 1 per day as a single dose. The final dose of baclofen was given on the 13th day of treatment. The infant was discharged home to the parents on the 18th day of life after demonstrating NAS scores consistently less than 8 (range 4 to 7) for 48 h off of the oral baclofen. The infant's neurological examination at the time of discharge was normal.
DISCUSSION
The Food and Drug Administration has categorized baclofen as category C for use in pregnancy, indicating that animal studies have shown adverse effects on the fetus and there are no controlled human studies, yet potential benefits may outweigh the risks.
8 Isolated case reports exist on the use of oral baclofen during pregnancy. Two of these cases describe normal neonatal outcome following intra-uterine exposure to baclofen, with maternal doses between 25 and 30 mg daily. 9, 10 A third case describes the use of baclofen to prevent seizures; however, the utility of baclofen in this case is a suspect, as the maternal dose was only 20 mg daily and the mother had been maintained on oxycodone at a dose of 50 mg daily. 7 The fourth case required baclofen for the control of seizures unresponsive to conventional pharmacological management, following intrauterine exposure of 80 mg daily of baclofen. 6 This case presents the unique use of baclofen for withdrawal in preterm neonate after exposure to high dose maternal baclofen (90 mg per day). We are confident that the etiology of withdrawal in this infant could be attributed to the placental transfer of the maternal baclofen to the neonate. The mother was on no other medications which would account for the constellation of symptoms described in this infant and toxicology screening for drugs of abuse were negative.
All of the current scoring tools used to quantify drug withdrawal in the neonate are designed to specifically target the term infant. Preterm infants tend to have less severe general symptoms and less central nervous system manifestations. 11 The preterm infant typically receives higher scores for high-pitched cry, tremors, poor feeding and emesis, whereas abnormalities in sleep patterns, hypertonicity, fever and diarrhea typically receive a lower score. 11 Yet in our case, the predominant symptoms included hypertonicity, abnormal sleep patterns, fever and loose stools, which mirrored symptoms of withdrawal seen in the term neonate. Further, amelioration of these symptoms was accomplished by administration of oral baclofen, with no notable side effects. Although not a commonplace, the clinician should be aware of the potential for withdrawal symptoms in the neonate following maternal use of oral baclofen, especially at higher doses.
